Cirrhosis Registry of Hospitalized Patients
Overview
Cirrhosis registry of consecutive adult consenting patients hospitalized with liver cirrhosis in the tertiary liver unit
Full Title of Study: “Registry of Adult Consenting Patients Admitted to the Liver Unit With Liver Cirrhosis”
Study Type
- Study Type: Observational [Patient Registry]
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: February 2, 2021
Detailed Description
On admission to F.D.Roosevelt Teaching Hospital / HEGITO Liver Unit (Div Hepatology, Gastroenterology and Liver Transplant), all the adult patients with liver cirrhosis are offered to participate. After providing informed consent, their demographic, clinical and laboratory / imaging data are uploaded by dedicated study person After discharge from the hospital, follow-up is recommended and uploaded to RH7 (if the follow-up visits take place at this institution [FDR]) Mortality data are uploaded from the national registry of dead on regular basis
Arms, Groups and Cohorts
- Adults with liver cirrhosis admitted to hospital liver unit
- Consenting adults admitted with liver cirrhosis; recorded/uploaded are demographic, clinical, laboratory and imaging data
Clinical Trial Outcome Measures
Primary Measures
- Frequency and type of decompensation of liver cirrhosis
- Time Frame: “1 year”
- Registrations reflect cirrhosis prevalence; decompensation are acute, chronic, or acute-on-chronic
- Mortality
- Time Frame: “1 year”
- Record mortality in registered cirrhotics
Secondary Measures
- Mortality
- Time Frame: 90-day
- Record mortality in registered cirrhotics
- Mortality
- Time Frame: 1 year
- Record mortality in registered cirrhotics
- Frailty
- Time Frame: On admission
- Measurement of the liver frailty index
Participating in This Clinical Trial
Inclusion Criteria
- liver cirrhosis (primarily on clinical grounds) – decompensating event leading to hospital admission – informed consent Exclusion Criteria:
- declined consent
Gender Eligibility: All
Minimum Age: 19 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
- Provider of Information About this Clinical Study
- Principal Investigator: Ľubomír Skladaný MD, PhD, Head, Department of Internal Medicine and HEGITO Liver Unit, Principal Investigator – F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
- Overall Official(s)
- Lubomir Skladany, MD PhD, Principal Investigator, F.D.Roosevelt Teaching Hospital, Banska Bystrica, Slovakia
- Overall Contact(s)
- Lubomir Skladany, MD, PhD, +421905482997, lubomir.skladany@gmail.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.